Bivalirudin in stable angina and acute coronary syndromes

Thomas A. Mavrakanas, Yiannis S. Chatzizisis

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

A parenteral anticoagulant is indicated in patients with acute coronary syndromes. Which anticoagulant should be preferred in each setting is not clearly established. Bivalirudin administration was considered in acute coronary syndromes after several clinical trials showed decreased bleeding risk with its use compared with the association of unfractionated heparin (UFH) with glycoprotein IIb/IIIa inhibitors (GPIs). Most recent data demonstrate that the bleeding benefit identified in the previous studies was not due to bivalirudin's properties but to higher bleeding incidence in the comparator arm due to the disproportional use of GPIs with heparin. This paper reviews clinical evidence on bivalirudin as anticoagulant in stable angina and acute coronary syndromes.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalPharmacology and Therapeutics
Volume152
DOIs
StatePublished - Jun 29 2015

Fingerprint

Stable Angina
Acute Coronary Syndrome
Anticoagulants
Platelet Glycoprotein GPIIb-IIIa Complex
Hemorrhage
Heparin
Clinical Trials
Incidence
bivalirudin

Keywords

  • Acute coronary syndrome
  • Angina
  • Bivalirudin
  • Heparin
  • Non-ST-elevation myocardial infarction
  • ST-elevation myocardial infarction

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Bivalirudin in stable angina and acute coronary syndromes. / Mavrakanas, Thomas A.; Chatzizisis, Yiannis S.

In: Pharmacology and Therapeutics, Vol. 152, 29.06.2015, p. 1-10.

Research output: Contribution to journalReview article

@article{2c6da332d06b427d9dac688c6eb0052f,
title = "Bivalirudin in stable angina and acute coronary syndromes",
abstract = "A parenteral anticoagulant is indicated in patients with acute coronary syndromes. Which anticoagulant should be preferred in each setting is not clearly established. Bivalirudin administration was considered in acute coronary syndromes after several clinical trials showed decreased bleeding risk with its use compared with the association of unfractionated heparin (UFH) with glycoprotein IIb/IIIa inhibitors (GPIs). Most recent data demonstrate that the bleeding benefit identified in the previous studies was not due to bivalirudin's properties but to higher bleeding incidence in the comparator arm due to the disproportional use of GPIs with heparin. This paper reviews clinical evidence on bivalirudin as anticoagulant in stable angina and acute coronary syndromes.",
keywords = "Acute coronary syndrome, Angina, Bivalirudin, Heparin, Non-ST-elevation myocardial infarction, ST-elevation myocardial infarction",
author = "Mavrakanas, {Thomas A.} and Chatzizisis, {Yiannis S.}",
year = "2015",
month = "6",
day = "29",
doi = "10.1016/j.pharmthera.2015.04.003",
language = "English (US)",
volume = "152",
pages = "1--10",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Bivalirudin in stable angina and acute coronary syndromes

AU - Mavrakanas, Thomas A.

AU - Chatzizisis, Yiannis S.

PY - 2015/6/29

Y1 - 2015/6/29

N2 - A parenteral anticoagulant is indicated in patients with acute coronary syndromes. Which anticoagulant should be preferred in each setting is not clearly established. Bivalirudin administration was considered in acute coronary syndromes after several clinical trials showed decreased bleeding risk with its use compared with the association of unfractionated heparin (UFH) with glycoprotein IIb/IIIa inhibitors (GPIs). Most recent data demonstrate that the bleeding benefit identified in the previous studies was not due to bivalirudin's properties but to higher bleeding incidence in the comparator arm due to the disproportional use of GPIs with heparin. This paper reviews clinical evidence on bivalirudin as anticoagulant in stable angina and acute coronary syndromes.

AB - A parenteral anticoagulant is indicated in patients with acute coronary syndromes. Which anticoagulant should be preferred in each setting is not clearly established. Bivalirudin administration was considered in acute coronary syndromes after several clinical trials showed decreased bleeding risk with its use compared with the association of unfractionated heparin (UFH) with glycoprotein IIb/IIIa inhibitors (GPIs). Most recent data demonstrate that the bleeding benefit identified in the previous studies was not due to bivalirudin's properties but to higher bleeding incidence in the comparator arm due to the disproportional use of GPIs with heparin. This paper reviews clinical evidence on bivalirudin as anticoagulant in stable angina and acute coronary syndromes.

KW - Acute coronary syndrome

KW - Angina

KW - Bivalirudin

KW - Heparin

KW - Non-ST-elevation myocardial infarction

KW - ST-elevation myocardial infarction

UR - http://www.scopus.com/inward/record.url?scp=84933679982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933679982&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2015.04.003

DO - 10.1016/j.pharmthera.2015.04.003

M3 - Review article

C2 - 25857452

AN - SCOPUS:84933679982

VL - 152

SP - 1

EP - 10

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -